These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7201588)

  • 1. Plasmapheresis decreases neuroelectric blocking activity in multiple sclerosis.
    Stefoski D; Schauf CL; McLeod BC; Haywood CP; Davis FA
    Neurology; 1982 Aug; 32(8):904-7. PubMed ID: 7201588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroelectric blocking activity and plasmapheresis in amyotrophic lateral sclerosis.
    Schauf CL; Antel JP; Arnason BG; Davis FA; Rooney MW
    Neurology; 1980 Sep; 30(9):1011-3. PubMed ID: 6252513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement-dependent serum: neuroelectric blocking activity in multiple sclerosis.
    Schauf CL; Schauf V; Davis FA; Mizen MR
    Neurology; 1978 May; 28(5):426-30. PubMed ID: 306076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathophysiological changes of inflammatory syndrome in multiple sclerosis after instituting therapeutic plasmapheresis.
    Vlaic S; Poalelungi V; Bălăeţ M; Purcărea VL; Bălăeţ C; Coculescu BI
    J Med Life; 2017; 10(1):50-53. PubMed ID: 28255377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone.
    Tindall RS; Walker JE; Ehle AL; Near L; Rollins J; Becker D
    Neurology; 1982 Jul; 32(7):739-43. PubMed ID: 7201110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of valproic acid by plasmapheresis in a patient treated for multiple sclerosis.
    Bastiaans DE; van Uden IW; Ruiterkamp RA; de Jong BA
    Ther Drug Monit; 2013 Feb; 35(1):1-3. PubMed ID: 23222689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study].
    Meca-Lallana JE; Rodríguez-Hilario H; Martínez-Vidal S; Saura-Luján I; Carretón-Ballester A; Escribano-Soriano JB; Martín-Fernández J; Genovés-Aleixandre A; Mateo-Bosch E; Fernández-Barreiro A
    Rev Neurol; 2003 Nov 16-30; 37(10):917-26. PubMed ID: 14634919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful immunoadsorption with membrane plasmapheresis for multiple sclerosis.
    Hosokawa S; Oyamaguchi A; Yoshida O
    ASAIO Trans; 1989; 35(3):576-7. PubMed ID: 2688722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis.
    Uchida A; Maida EM; Lenzhofer R; Micksche M
    Immunobiology; 1982 Feb; 160(5):392-402. PubMed ID: 6175561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful treatment with additional plasmapheresis for the exacerbation of acute neurological symptoms in a girl with multiple sclerosis].
    Mogami Y; Yamada K; Toribe Y; Yanagihara K; Mano T; Suzuki Y
    No To Hattatsu; 2011 Jan; 43(1):36-40. PubMed ID: 21400930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmapheresis in multiple sclerosis: preliminary findings.
    Dau PC; Petajan JH; Johnson KP; Panitch HS; Bornstein MB
    Neurology; 1980 Oct; 30(10):1023-8. PubMed ID: 6448360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon inhibitor factor predicting success of plasmapheresis in patients with multiple sclerosis.
    Medenica RD; Mukerjee S; Huschart T; Corbitt W
    J Clin Apher; 1994; 9(4):216-21. PubMed ID: 7759466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroelectric blocking factors in multiple sclerosis and normal human sera.
    Seil FJ; Leiman AL; Kelly JM
    Arch Neurol; 1976 Jun; 33(6):418-22. PubMed ID: 938266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses.
    Faissner S; Nikolayczik J; Chan A; Hellwig K; Gold R; Yoon MS; Haghikia A
    J Neurol; 2016 Jun; 263(6):1092-8. PubMed ID: 27039388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasmapheresis in multiple sclerosis].
    Fuchs S; Pogglitsch H; Ladurner G; Lechner H
    Wien Klin Wochenschr; 1984 Jan; 96(2):67-9. PubMed ID: 6710999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmapheresis in multiple sclerosis: preliminary study.
    Weiner HL; Dawson DM
    Neurology; 1980 Oct; 30(10):1029-33. PubMed ID: 7191492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma exchange (PE) and lymphocytapheresis (LCA) in multiple sclerosis (MS).
    Höcker P; Stellamor V; Summer K; Mann M
    Int J Artif Organs; 1984 Jan; 7(1):39-42. PubMed ID: 6698632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma exchange in multiple sclerosis.
    Guarnieri BM; Capparelli R; Fratiglioni L; Inzitari D; Sità D; Amaducci L; Avanzi G; Biani D; Franco C; Lombardo R
    Int J Artif Organs; 1985 Jul; 8(4):215-20. PubMed ID: 3902665
    [No Abstract]   [Full Text] [Related]  

  • 19. Trace elements and plasmapheresis.
    Hosokawa S; Oyamaguchi A; Yoshida O
    Int J Artif Organs; 1991 Apr; 14(4):242-5. PubMed ID: 2060990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis.
    Hauser SL; Fosburg M; Kevy S; Weiner HL
    Prog Clin Biol Res; 1982; 106():239-54. PubMed ID: 6184727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.